Uro-Vaxom^® and the Management of Recurrent Urinary Tract Infection in Adults: A Randomized Multicenter Double-Blind Trial

Magasi, P; Pánovics, J; Illés, A; Nagy, Marion

doi:10.1159/000475363

Cited by 59 publications

(55 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the complex vaccine front, Uro-Vaxom is a daily oral capsule containing a lyophilized mix of membrane proteins from 18 E. coli strains (95, 253). The formulation elicits a number of immunological effects in vitro (230,278,289,290), generates specific antibodies in mice and humans (15,51,117,233), and generally reduces the incidence of UTI in patients (22,51,95,156,160,232,253). Unfortunately, complications can occur due to toxicity, and the necessity of daily administration presents supply and compliance issues.…”

Section: Weapons Systems: Current and Proposed Treatments And Vaccinementioning

confidence: 99%

Waging War against UropathogenicEscherichia coli: Winning Back the Urinary Tract

2010

View full text Add to dashboard Cite

Urinary tract infection (UTI) caused by uropathogenic Escherichia coli (UPEC) is a substantial economic and societal burden-a formidable public health issue. Symptomatic UTI causes significant discomfort in infected patients, results in lost productivity, predisposes individuals to more serious infections, and usually necessitates antibiotic therapy. There is no licensed vaccine available for prevention of UTI in humans in the United States, likely due to the challenge of targeting a relatively heterogeneous group of pathogenic strains in a unique physiological niche. Despite significant advances in the understanding of UPEC biology, mechanistic details regarding the host response to UTI and full comprehension of genetic loci that influence susceptibility require additional work. Currently, there is an appreciation for the role of classic innate immune responses-from pattern receptor recognition to recruitment of phagocytic cells-that occur during UPEC-mediated UTI. There is, however, a clear disconnect regarding how factors involved in the innate immune response to UPEC stimulate acquired immunity that facilitates enhanced clearance upon reinfection. Unraveling the molecular details of this process is vital in the development of a successful vaccine for prevention of human UTI. Here, we survey the current understanding of host responses to UPEC-mediated UTI with an eye on molecular and cellular factors whose activity may be harnessed by a vaccine that stimulates lasting and sterilizing immunity. MISSION: ERADICATE UPEC-MEDIATED UTIUrinary tract infection (UTI) is one of the most common infections in humans. Bacteria present in fecal matter inoculate the periurethral area, then the bladder (124, 176, 291), causing symptoms clinically termed cystitis. Left untreated, bacteria ascend the ureters to the kidney and establish a secondary infection, acute pyelonephritis. At this juncture, there is risk of permanent renal scarring, and bacteria can access the bloodstream (282). It is estimated that 40% of women and 12% of men will experience a symptomatic UTI, with incidences peaking in their early 20s or after age 85, respectively (75, 185). Approximately 25% of these women will experience recurrence within 6 to 12 months (75, 185). Uropathogenic Escherichia coli (UPEC) is the most common etiological agent responsible for uncomplicated UTI (93, 94,282). Uropathogenic strains are classified as extraintestinal pathogenic E. coli, a broad grouping of E. coli that cause diseases other than gastroenteritis and typically lack a type III secretion system (171,220,221,283,284). Nonetheless, UPEC strains express an assortment of virulence and fitness factors that aid in successful colonization of the mammalian urinary tract (126,136). In the United States alone, the estimated annual societal cost of UTI is more than 3 billion dollars (159).Despite a relatively in-depth knowledge base for UPEC physiology and virulence mechanisms (reviewed in references 54, 126, 136, and 284), no licensed vaccine to prevent UTI exists in the Un...

show abstract

Section: Weapons Systems: Current and Proposed Treatments And Vaccinementioning

confidence: 99%

Waging War against UropathogenicEscherichia coli: Winning Back the Urinary Tract

2010

View full text Add to dashboard Cite

show abstract

“…The five studies [26][27][28][29][30] retained for further analysis present a large amount of commonalities, albeit differing in some aspects. In three studies [27][28][29][30] also men were included, but always less than 20% of the total patients.…”

Section: Product 'A': Om-89 (Uro-vaxom ® )mentioning

confidence: 99%

“…In three studies [27][28][29][30] also men were included, but always less than 20% of the total patients. Unfortunately, the results could not be stratified by gender.…”

Section: Product 'A': Om-89 (Uro-vaxom ® )mentioning

confidence: 99%

Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis

Naber

Cho

Matsumoto

et al. 2009

International Journal of Antimicrobial Agents

141

View full text Add to dashboard Cite

“…The efficacy of Uro-Vaxom Ⓡ for the prophylaxis of recurrent UTI was tested in placebo-controlled, double-blinded studies [54][55][56][57][58]. In these trials, patients taking one Uro-Vaxom Ⓡ capsule per day for 90 days experienced considerably less recurrent UTIs than patients taking placebo.…”

Section: Prevention Of Recurrent Urinary Tract Infectionmentioning

confidence: 99%

The Association between Chronic Inflammation and Recurrent Cystitis in Women

Chung

2016

Urogenit Tract Infect

View full text Add to dashboard Cite

Recurrent urinary tract infection is a common infectious disease seen in the clinic. It is very prevalent in women; as many as 15% of women develop urinary tract infection each year, and at least 25% have one or more recurrences. Chronic inflammation and increased urothelial apoptosis reflect a common pathophysiology in various lower urinary tract dysfunctions, causing bladder storage symptoms. It has been suggested that chronic inflammation could be associated with overactive detrusor and increased levels of urinary nerve growth factor and creatinine. The level of urinary nerve growth factor may decrease after an effective antimuscarinic therapy. Recurrent urinary tract infection could be prevented by using nonsteroidal anti-inflammatory drugs or cyclooxygenase-2 inhibitors. Intravesical hyaluronate and chondroitin sulfate reduce the incidence of recurrent bacterial cystitis, and treatment with hyaluronate targets bacterial adherence to the bladder mucosa in interstitial cystitis/bladder pain syndrome. This article reviews the pathophysiology of chronic inflammation of the bladder and investigates the association between chronic inflammation and recurrent urinary tract infection.

show abstract

Uro-Vaxom^® and the Management of Recurrent Urinary Tract Infection in Adults: A Randomized Multicenter Double-Blind Trial

Cited by 59 publications

References 5 publications

Waging War against UropathogenicEscherichia coli: Winning Back the Urinary Tract

Waging War against UropathogenicEscherichia coli: Winning Back the Urinary Tract

Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis

The Association between Chronic Inflammation and Recurrent Cystitis in Women

Contact Info

Product

Resources

About